Tony Berberabe's profile photo

Tony Berberabe

Cranbury

Assistant Managing Editor at Targeted Oncology

Assistant Managing Editor, Targeted Therapies in Oncology. Tweets are my own.

Featured in: Favicon targetedonc.com Favicon newsbreak.com Favicon cancernetwork.com Favicon onclive.com Favicon curetoday.com Favicon urologytimes.com Favicon oncnursingnews.com Favicon cgtlive.com Favicon ourcommunitynow.com Favicon ajmc.com

Articles

  • Adjuvant Atezolizumab Plus mFOLFOX6 Improves DFS in dMMR Colon Cancer

    1 week ago | onclive.com | Tony Berberabe

    The addition of atezolizumab (Tecentriq) to mFOLFOX6 (modified oxaliplatin, leucovorin, and fluorouracil) led to a significant improvement in disease-free survival (DFS) vs mFOLFOX6 alone as adjuvant therapy in patients with stage III, mismatch repair–deficient (dMMR) colon cancer, according to results from the phase 3 ATOMIC trial (NCT02912559) that were presented during a press briefing at the 2025 ASCO Annual Meeting.

  • ProMPT Enhances NGS Reports to Delineate Treatment Complexities

    1 week ago | targetedonc.com | Tony Berberabe

    Oncology treatments continue to grow in complexity, with an increasing reliance on biomarker-driven therapies. This evolution makes it difficult for clinicians to stay current on emerging approaches. Compounding the challenge, genomic data from next-generation sequencing (NGS) reports are often confusing, difficult to extract, and not easily searchable.

  • PARP Inhibitors Show Promising Response and Clinical Benefit in BRCA-Altered Uterine Leiomyosarcoma

    1 week ago | targetedonc.com | Tony Berberabe

    Patients with BRCA-altered uterine leiomyosarcoma (LMS) treated with PARP inhibitors demonstrated encouraging outcomes, including an overall response rate (ORR) of 46%, a clinical benefit rate (CBR) of 62%, and a median progression-free survival (PFS) of 13.2 months (range, 1.0–71.9 months), according to a small retrospective study published in JCO Precision Oncology. The analysis included 534 patients with uterine sarcoma, 40 of whom harbored BRCA alterations.

  • Panitumumab Improves Outcomes in RAS/BRAF Wildtype Colon Cancer

    2 weeks ago | oncnursingnews.com | Tony Berberabe

    Panitumumab (Vectibix) added to neoadjuvant FOLFOX (folinic acid, fluorouracil, and oxaliplatin) chemotherapy improved survival and reduced recurrence in patients with locally advanced colon cancer (LACC) and RAS/BRAF wildtype tumors, according to exploratory findings from the FOxTROT trial (ISRCTN838426) published in Annals of Oncology.1In the RAS/BRAF wild-type population, panitumumab plus FOLFOX outperformed FOLFOX alone across multiple end points.

  • Mature Data Confirm Benefit of Early Rituximab vs Watchful Waiting in Asymptomatic Follicular Lymphoma

    2 weeks ago | targetedonc.com | Tony Berberabe

    Long-term follow-up from a phase 3 trial (NCT00112931) has reaffirmed that early rituximab (Rituxan) monotherapy significantly delays the need for new treatment in patients with advanced-stage, asymptomatic, low tumor burden follicular lymphoma. After 15 years, the data reveal stark differences in outcomes between treatment strategies.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
319
Tweets
486
DMs Open
No
Tony Berberabe
Tony Berberabe @OncBiz_Wiz
20 May 24

RT @TargetedOnc: Check out our coverage on a phase 1/2 trial (NCT04474470) evaluating NT219 in combination with cetuximab (Erbitux) in squa…

Tony Berberabe
Tony Berberabe @OncBiz_Wiz
15 May 24

Telehealth Framework Sets Stage for Decentralized Clinical Trials in Oncology https://t.co/G5Gd8AyOHc via @targetedonc

Tony Berberabe
Tony Berberabe @OncBiz_Wiz
11 Sep 23

@ilca2023 - Are there any press releases that came out of ILCA 2023 and are they available?